Loading...
Relapsed or primary refractory AML: moving past MEC and FLAG-ida
Treatment of relapsed and refractory acute myeloid leukemia (AML) is still very challenging, with poor response rates and low chance for cure. This is especially true when treating patients who are elderly, have multiple comorbidities, or who are too unfit for traditional salvage chemotherapy regime...
Saved in:
| Published in: | Curr Opin Hematol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Lippincott Williams And Wilkins
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7015186/ https://ncbi.nlm.nih.gov/pubmed/31904664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000561 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|